The increasing drug prices in Europe

Vytenis Andriukaitis

Vytenis Andriukaitis, Member of the EC in charge of Health and Food Safety, and Carlos Moedas, Member of the EC in charge of Research, Science and Innovation, awarded the “Horizon Prize – Better Use of Antibiotics” and “The EU Health Awards for NGO’s fighting Antimicrobial Resistance” at a ceremony hold in Leuven. © European Union , 2017 / Source: EC – Audiovisual Service / Photo: Lukasz Kobus.

This article was written by one of our passionate readers, Mrs Rachel Everly. The opinions expressed within reflect only the writer’s views and not The European Sting’s position on the issue.

Rising drug prices have not been a recent issue, it has always been a part and parcel of the medical expenses. Not only is the United States suffering through a spike in the prices of medicines, but European medical bills have taken a toll for the worse as well. Prior to that, Europe had refrained from huge raises in the prices and until 2011, the selling price of many prescription pills had been steadily low.

Since most of the European nations are funding the healthcare systems on a government level, it is only understandable that they would want to keep a close track of the pharmaceutical industry. Due to this reason, the European Pharmaceutical companies are known to work on laws and regulations that restrict them from increasing the prices of the medicines for more than once a year. The price, profits, and comparison of the prices with the international market were always screened and assessed throughout the year without adjusting the prices.

In 2011, many European countries saw a gradual rise in multiple medicines and the rates have been rising ever since, without any restriction. This will affect many consumers and the fee structure of their individual health plans. To counter this problem, European Parliament’s environment Committee (ENVI) is favoring a non-legislative proposition that will strive for making these products more widespread in the European region. However, this must not be confused with an actual law being added in the region’s policies, as it is merely a resolution waiting to be approved by the authorities. With time, it may be considered and the European Union may only then choose to implement it.

The price of specific drugs has been a matter of huge concern for the public. Looking at the prices of those medicines in the previous years has shown an increase in prices for as much as over 1000%. Drugs that are used for leukemia patients have an increased price of 1225%, while tamoxifen, which is used primarily for breast cancer has risen by 1080% from 2011 to 2016. A chemotherapy drug has seen a spike of 1500% but later was fined for 5 million euros for an illegal increase in the price.

Charges of relatively new drugs that have little to no competition are also in the race for increasing their prices up to stupendous amounts. Multiple Sclerosis and Cancer treatment drugs are hiking due to lack of competition and insurance companies and pharmacy beneficiaries are losing against keeping these companies at bay.

The setting not only destabilizes the people who are insured but deeply affects the people who chose not to be insured or cannot afford healthcare. Previously, a person who could not have afforded to have themselves operated could find comfort in medicines. The same is not the case anymore and medical prescription drugs have become even more unattainable than before for many uninsured people out there. Seniors who have retired and do not have an insurance plan can also be looking at paying higher prices than they have previously been paying.

It has been debated for more than one year that the prices of the drugs do not represent the true cost of its production. It is concluded that the price of its manufacturing is far lower than the price label put on the product.  Most of these increments in prices have more to do with profits for these drug manufacturing companies and little to do with the increasing demands and lack of supply. To counter any research and development aspect of a new drug and decrease its cost, the patient-driven research is promoted. This means that the patient can sponsor the research and have the cure developed and tested.

Another speculation that has also been made is that due to the fact that they are only allowed to raise the costs once a year. This has made the marketers overly cautious and in order to withstand any possible demand and supply problem, or a price hike in the global market, they increase their rates by a huge percentage.

In order to provide a safer and more affordable plan for the healthcare system, the government, the people, and the drug manufacturers must work together. More and more efforts have been put on by EU health ministers in 2016 to warn the pharmaceuticals to lower the prices down as it has created a market that is highly unapproachable.

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Join the Hive!

Featured Stings

EU Trust Fund for Africa: Can it be beneficial for Italy and tackle the migration crisis in the Mediterranean?

Germany takes cover from Trump in Eurozone and decides to pay for it

Commission’s action plan: financial world mandatory links to environmental targets

The migration crisis is slowly melting the entire EU edifice

Ecofin: ‘The Friday battle’ for the banking union

Worldwide consumer confidence has shot up to its highest level for four years according to a survey of 130 Global Retail leaders

COP21 Business update: Companies urge now for carbon pricing as coal is still a big issue

A Sting Exclusive: “Leading by example! EU must push for UN deal to avoid dangerous climate change”, European Parliament Vice-President Ulrike Lunacek cries out from Brussels

Italy can stand the US rating agencies’ meaningless degrading

EU Budget: InvestEU Programme to support jobs, growth and innovation in Europe

Civil society organisations disenchanted with “Youth Guarantee”

The consequences of Brexit seen by a European young entrepreneur

A Sting Exclusive: Towards better business opportunities for the EU and its neighbours, Commissioner Hahn live from European Business Summit 2015

Quality Education on the table at the European Parliament

Parliament votes for €1 billion in aid to Ukraine

Commission: Gifts of €6 billion and free trainees to ‘help’ poor employers

New chapters in EU-China trade disputes

Roxane in Cambodia

‘Worst devastation I have seen,’ says UN refugee envoy Angelina Jolie, as she visits West Mosul

“16+1” Cooperation injects new vigor into China-Europe cooperation

Russia won’t let Ukraine drift westwards in one piece

Shifting Tides: Policy Challenges and Opportunities for the G-20

This house is made entirely out of recycled rubbish

WEF Davos 2016 LIVE: “Employment contracts today are a reducing share of the workforce”, scientists worry in Davos that the 4th industrial revolution threatens employment globally

The battle for the 2016 EU Budget to shake the Union; Commission and Parliament vs. Germany

Trump to subject the Fed, challenge the ECB and make Wall St. bankers even richer

MWC 2016 LIVE: BT chief aims to be at UK 5G forefront

ECB again to subsidize euro area banks with more than one trillion euro

The Chinese film boom luring Hollywood’s stars

Eurozone closer to a deflation – stagnation trap

Income inequality threatens the socio-political structures in developed countries

Asylum: deal to update EU fingerprinting database

The European Parliament floating over the South China Sea

Commission sets moderate greenhouse gas reduction targets for 2030

The Commission favours the cultivation of more GMOs in Europe

Achieving targets on energy helps meet other Global Goals, UN forum told

The eighth round of TTIP negotiations concludes in Brussels amid scepticism and new fears

The miserables and the untouchables of the economic crisis

No hard drivers in sight to remodel the stagnating affairs of the EU

Eurozone: Inflation plunge to 0.4% in July may trigger cataclysmic developments

Bankers don’t go to jail because they are more equal than us all

Knowledge management and entrepreneurship: short term vs. long term perspective

Trump ‘used’ G20 to side with Putin and split climate and trade packs

India’s economy is growing fast, but its poorest areas lag behind. Here’s why this could be about to change

De-escalation of fighting in Hodeida is key to ‘long-overdue’ restart of Yemen peace talks: UN envoy

MWC 2016 LIVE: T-Mobile US reveals 5G trial plans

MWC 2016 Live: Industrial world prepares to reap digital benefits

“Financial crisis will not happen in China!”, the Chinese Premier underlines from Switzerland; the Sting reports live from World Economic Forum 2015 in Davos

Italy’s dilemma after Merkel-Hollande agreed loose banking union

Will Merkel ever steer the EU migration Titanic and restore her power in Germany?

Does the West reserve the fate of Libya and Syria for others? How does this relate to the EU’s Neighborhood Policy?

Brain Drain remains a crucial and unresolved issue

Free trade agreement between EU and India?

Is Erdogan ready to tear down the bridges with Europe and the West?

EU budget: Making the EU fit for its role as strong global actor

Parliament backs a modernised EU electoral law

How to help companies become global defenders of LGBTI rights

EU Top Jobs summit ended with no agreement: welcome to Europe’s quicksand!

Regional policies slowed down by EU bureaucracy

COP21 Breaking News_10 December: UN Climate Chief Calls for Final Push to Meet Adaptation Fund Goal Very Close to Target

More Stings?

Trackbacks

  1. […] The cost of new medical technologies and drugs remains the primary cause of the high rate of medical inflation: this is why a discussion at European level with the European Federation of Pharmaceutical Industries and Associations is still open: drug pricing is at the top of the bill. […]

  2. […] Il costo di nuove tecnologie e medicinali rimane la causa principale dell’aumento dei tassi di inflazione medica: questo è il motivo per cui a livello europeo è in corso una discussione con l’Associazione Europea delle Compagnie Farmaceutiche. Il punto principale dell’agenda è sempre quello: il continuo aumento dei medicinali. […]

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s